Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03029598 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

DRUG: Carboplatin
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]